Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Cited by (12,156)

Items 901–1,000 of 12,156

1. Sodium–glucose cotransporter 2 inhibitor‐induced changes in body composition and simultaneous changes in metabolic profile: 52‐week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
   Takashi Sasaki, Masahiro Sugawara, Masahiro Fukuda · 2018 · Journal of Diabetes Investigation
2. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway
   Ziyu Meng, Xiaohuan Liu, Ting Li, Ting Fang, Ying Cheng, Liping Han, Bei Sun, Liming Chen · 2021 · International Immunopharmacology
3. Effects of canagliflozin on human myocardial redox signalling: clinical implications
   Hidekazu Kondo, Ioannis Akoumianakis, Ileana Badi, Nadia A. Akawi, Christos P. Kotanidis, Murray Polkinghorne, Ilaria Stadiotti, Elena Sommariva, Alexios S. Antonopoulos, Maria Cristina Carena et al. · 2021 · European Heart Journal
4. Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes
   Xinru Deng, Chenhong Zhang, Pengxu Wang, Wei Wei, Xiaoyang Shi, Pingping Wang, Junpeng Yang, Limin Wang, Shasha Tang, Yuanyuan Fang et al. · 2022 · The Journal of Clinical Endocrinology & Metabolism
5. Diabetic cardiomyopathy: Clinical phenotype and practice
   Xudong Zhao, Shengwang Liu, Xiao Wang, Yibing Chen, Pai Pang, Qianjing Yang, Jingyi Lin, Shuaishuai Deng, WU Shen-tao, Guanwei Fan et al. · 2022 · Frontiers in Endocrinology
6. Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial
   Moritz Hundertmark, Amanda Adler, Charalambos A. Antoniades, Ruth L. Coleman, Julian Leether Griffin, Rury R. Holman, Hanan Lamlum, Jisoo Lee, Daniel Massey, Jack J. J. J. Miller et al. · 2023 · Circulation
7. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure
   Marso, Steven P., Baeres, Florian M.M., Bain, Stephen C., Goldman, Bryan, Husain, Mansoor, Nauck, Michael A., Poulter, Neil R., Pratley, Richard E., Thomsen, Anne Bloch, Buse, John B. · 2020 · Journal of the American College of Cardiology
8. Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
   Avivit Cahn, William T. Cefalu · 2016 · Diabetes Care
9. Sodium‐glucose co‐transporter‐2 inhibitors and diabetic ketoacidosis: <scp>A</scp> n updated review of the literature
   Bonora, Benedetta Maria, Avogaro, Angelo, Fadini, Gian Paolo · 2018 · Diabetes, Obesity and Metabolism
10. Diabetes in Older People
    Graydon S. Meneilly, Aileen Knip, David B. Miller, Diana Sherifali, Daniel Tessier, Afshan Zahedi · 2018 · Canadian Journal of Diabetes
11. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs
    Giuseppe Patti, Ilaria Cavallari, Felicita Andreotti, Paolo Calabrò, Plinio Lorenzo Cirillo, Gentian Denas, Mattía Galli, Enrica Golia, Ernesto Maddaloni, Rossella Marcucci et al. · 2018 · Nature Reviews Cardiology
12. DPP-4 Inhibition and the Path to Clinical Proof
    Bo Åhrén · 2019 · Frontiers in Endocrinology
13. Safety of Sodium-Glucose Co-Transporter 2 Inhibitors
    Janet B. McGill, Savitha Subramanian · 2019 · The American Journal of Cardiology
14. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease
    Zien Zhou, Meg Jardine, Qiang Li, Brendon Lange Neuen, Christopher Paul Cannon, Dick de Zeeuw, Robert Edwards, Adeera Levin, Kenneth W. Mahaffey, Vlado Perkovic et al. · 2021 · Stroke
15. COMORBIDITIES IN PRACTICE. CLINICAL GUIDELINES
    Р. Г. Оганов, И. Н. Денисов, Vladimir I. Simanenkov, Игорь Геннадьевич Бакулин, Н. В. Бакулина, Болдуева Светлана Афанасьевна, О. Л. Барбараш, Natalia P. Garganeeva, Vladimir L. Doshchitsin, Oksana M. Drapkina et al. · 2017 · CARDIOVASCULAR THERAPY AND PREVENTION
16. DECLARE‐TIMI 58: Participants’ baseline characteristics
    Itamar Raz, Ofri Mosenzon, Marc P. Bonaca, Avivit Cahn, Eri Toda Kato, Michael G. Silverman, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding et al. · 2018 · Diabetes Obesity and Metabolism
17. Changing use of antidiabetic drugs in the UK: trends in prescribing 2000–2017
    Samantha Wilkinson, Ian Douglas, Heide A. Stirnadel-Farrant, Damian G. Fogarty, Ana Pokrajac, Liam L Smeeth, Laurie A. Tomlinson · 2018 · BMJ Open
18. Carbotoxicity—Noxious Effects of Carbohydrates
    Guido Kroemer, Carlos López-Otı́n, Frank Madeo, Rafael de Cabo · 2018 · Cell
19. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
    Kristian B. Filion, Lisa Marie Lix, Oriana HY Yu, Sophie Dell’Aniello, Antonios Douros, Baiju R. Shah, Audray St-Jean, Anat Fisher, Éric Tremblay, Shawn Bugden et al. · 2020 · BMJ
20. Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy
    Biff F. Palmer, Deborah J. Clegg · 2021 · Clinical Journal of the American Society of Nephrology
21. Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease
    Joshua D. Hutcheson, Claudia Goettsch · 2023 · Circulation Research
22. Hyperglycaemic Impairment of PAR2-Mediated Vasodilation: Prevention by Inhibition of Aortic Endothelial Sodium-Glucose-Co-Transporter-2 and Minimizing Oxidative Stress
    El-Daly, Mahmoud, Pulakazhi Venu, Vivek Krishna, Saifeddine, Mahmoud, Mihara, Koichiro, Kang, Sean, Fedak, Paul W.M., Alston, Laurie A., Hirota, Simon A., Ding, Hong, Triggle, Chris R. et al. · 2018 · Vascular Pharmacology
23. A Unified Pathophysiological Construct of Diabetes and its Complications
    Stanley S. Schwartz, Solomon Epstein, Barbara E. Corkey, Struan F.A. Grant, James R. Gavin, Richard B. Aguilar, Mary E. Herman · 2017 · Trends in Endocrinology and Metabolism
24. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low‐grade inflammation the neglected component?
    Francesco Prattichizzo, Valeria De Nigris, Stefano Micheloni, Lucia La Sala, Antonio Ceriello · 2018 · Diabetes Obesity and Metabolism
25. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits
    Elisa Marilly, Judith Cottin, Natalia Cabrera, Catherine Cornu, Rémy Boussageon, Philippe Moulin, Jean‐Christophe Lega, François Gueyffier, Michel Cucherat, Guillaume Grenet · 2022 · Diabetologia
26. Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
    Mechanick, Jeffrey I., Farkouh, Michael E., Newman, Jonathan D., Garvey, W. Timothy · 2020 · Journal of the American College of Cardiology
27. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial
    Ye, Nan, Jardine, Meg J., Oshima, Megumi, Hockham, Carinna, Heerspink, Hiddo J.L., Agarwal, Rajiv, Bakris, George, Schutte, Aletta E., Arnott, Clare, Chang, Tara I. et al. · 2021 · Circulation
28. Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes
    Samy Hadjadj, Julio Rosenstock, Thomas W. Meinicke, Hans Juergen Woerle, Uli C. Broedl · 2016 · Diabetes Care
29. Metabolic Support for the Heart: Complementary Therapy for Heart Failure?
    Ward Heggermont, Anna‐Pia Papageorgiou, Stephane R B Heymans, Marc van Bilsen · 2016 · European Journal of Heart Failure
30. A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses
    Maloney, Alan, Rosenstock, Julio, Fonseca, Vivian · 2019 · Clinical Pharmacology &amp; Therapeutics
31. A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis
    Julie Celine Refardt, Cornelia Imber, Clara Odilia Sailer, Nica Jeanloz, Laura Potasso, Alexander Kutz, Andrea Widmer, Sandrine Andrea Urwyler, Fahim Ebrahimi, D. Vogt et al. · 2020 · Journal of the American Society of Nephrology
32. Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
    Yue-Ming Gao, Songtao Feng, Yi Wen, Tao‐Tao Tang, Bin Wang, Bi‐Cheng Liu · 2022 · EBioMedicine
33. Exploring the Complex Connection Between Diabetes and Cardiovascular Disease: Analyzing Approaches to Mitigate Cardiovascular Risk in Patients With Diabetes
    FNU Jyotsna, Areeba Ahmed, Kamal Kumar, Paramjeet Kaur, Mitul Hareshkumar Chaudhary, Sagar Kumar, Ejaz Ahmad Khan, Bushra Khanam, Syeda Urooba Shah, Giustino Varrassi et al. · 2023 · Cureus
34. The Prognostic Value of Fasting Plasma Glucose, Two-Hour Postload Glucose, and HbA1c in Patients With Coronary Artery Disease: A Report From EUROASPIRE IV
    Shahim, Bahira, De Bacquer, Dirk, De Backer, Guy, Gyberg, Viveca, Kotseva, Kornelia, Mellbin, Linda, Schnell, Oliver, Tuomilehto, Jaakko, Wood, David, Rydén, Lars · 2017 · Diabetes Care
35. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials
    Singh, Awadhesh Kumar, Singh, Ritu · 2020 · Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews
36. Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism
    François Briand, Eric Mayoux, Emmanuel Brousseau, Noémie Burr, Isabelle Urbain, Clément Costard, Michael Mark, Thierry Sulpice · 2016 · Diabetes
37. Pharmacological management of nonalcoholic fatty liver disease
    Barb, Diana, Portillo-Sanchez, Paola, Cusi, Kenneth · 2016 · Metabolism
38. The pharmacological management of metabolic syndrome
    Julie Rask Larsen, Lorena Dima, Christoph Ulrich Correll, Peter Manu · 2018 · Expert Review of Clinical Pharmacology
39. Update on heart failure management and future directions
    Hong‐Mi Choi, Myung‐Soo Park, Jong‐Chan Youn · 2018 · The Korean Journal of Internal Medicine
40. Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative–inflammatory–apoptotic pathway
    Entesar Farghaly Amin, Rehab Ahmed Rifaai, Rania Abdellatif · 2020 · Fundamental and Clinical Pharmacology
41. Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials
    Stephan von Haehling, Michael E. Arzt, Wolfram Doehner, Frank Edelmann, Ruben Evertz, Nicole Ebner, Christoph Herrmann‐Lingen, Tania Garfias‐Veitl, Michael Johann Koziolek, Michel Noutsias et al. · 2020 · European Journal of Heart Failure
42. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
    Luna-Marco, Clara, Iannantuoni, Francesca, Hermo-Argibay, Alberto, Devos, Deédeni, Salazar, Juan D., Víctor, Víctor M., Rovira-Llopis, Susana · 2024 · Free Radical Biology and Medicine
43. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis.
    Tsai, Wen-Hsuan, Chuang, Shih-Ming, Liu, Sung-Chen, Lee, Chun-Chuan, Chien, Ming-Nan, Leung, Ching-Hsiang, Liu, Shu-Jung, Shih, Hong-Mou · 2021 · Scientific Reports
44. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes
    Matthew James O’Brien, Susan Karam, Amisha Wallia, Raymond H. Kang, Andrew Cooper, Nicola Lancki, Margaret R. Moran, David T. Liss, Theodore A. Prospect, Ronald T. Ackermann · 2018 · JAMA Network Open
45. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure
    Binayak Sinha, Samit Ghosal · 2019 · Diabetes Research and Clinical Practice
46. Diabetes and Cardiovascular Disease: an Update
    Almourani, Rajaa, Chinnakotla, Bhavana, Patel, Richa, Kurukulasuriya, L. Romayne, Sowers, James · 2019 · Current Diabetes Reports
47. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks
    Rachel J. Perry, Gerald I. Shulman · 2020 · Journal of Biological Chemistry
48. Empagliflozin Inhibits Na+/H+ Exchanger Activity in Human Atrial Cardiomyocytes
    Maximilian Trum, Johannes Riechel, Simon Lebek, Steffen Pabel, Samuel Tobias Sossalla, Stephan W. Hirt, Michael E. Arzt, Lars Siegfried Maier, Stefan Wagner · 2020 · ESC Heart Failure
49. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
    James R. Thrasher · 2017 · The American Journal of Medicine
50. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies
    James R. Thrasher · 2017 · The American Journal of Cardiology
51. SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus
    David A. Hess, Daniella C. Terenzi, Justin Z. Trac, Adrian Quan, Tamique Mason, Mohammed A. Al-Omran, Deepak L. Bhatt, Natasha Dhingra, Ori David Rotstein, Lawrence A. Leiter et al. · 2019 · Cell Metabolism
52. Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists
    Tanya Wilcox, Christophe E.M. De Block, Arthur Z. Schwartzbard, Jonathan D. Newman · 2020 · Journal of the American College of Cardiology
53. The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion
    Sergiy Sukhanov, Yusuke Higashi, Tadashi Yoshida, Srinivas Mummidi, Annayya Rao Aroor, Jacob J. Russell, Shawn B. Bender, Vincent Gerard DeMarco, Bysani Chandrasekar · 2020 · Cellular Signalling
54. Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
    Manfred Hecking, Adnan Sharif, Kathrin Eller, Trond Geir Jenssen · 2020 · Transplant International
55. Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy
    Lin Wang, Yin Cai, Liguo Jian, Chi Wai Cheung, Liangqing Zhang, Zhengyuan Xia · 2021 · Cardiovascular Diabetology
56. Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis
    Walter M. Masson, Augusto Lavalle Cobo, Juan Patricio Nogueira · 2021 · Cells
57. Hyperglycemia Induces Trained Immunity in Macrophages and Their Precursors and Promotes Atherosclerosis
    Laurienne Edgar, Naveed Akbar, Adam T. Braithwaite, Thomas Krausgruber, Héctor Gallart‐Ayala, Jade D. Bailey, Alastair Corbin, Tariq E. Khoyratty, Joshua T. Chai, Mohammad Alkhalil et al. · 2021 · Informationszentrum Lebenswissenschaften (ZB MED)
58. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
    Arjun K. Pandey, Deepak L. Bhatt, Avinash K Pandey, Nikolaus Marx, Francesco Cosentino, Ambarish Pandey, Subodh Verma · 2023 · European Heart Journal
59. Metabolic Messengers: ketone bodies
    Alisa B. Nelson, Eric D. Queathem, Patrycja Puchalska, Peter A. Crawford · 2023 · Nature Metabolism
60. Diabetic Vasculopathy: Molecular Mechanisms and Clinical Insights
    George Jia, Hetty Bai, Bethany Mather, Michael A. Hill, Guanghong Jia, James R. Sowers · 2024 · International Journal of Molecular Sciences
61. Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project
    Zhou, Mengge, Liu, Jing, Hao, Yongchen, Liu, Jun, Huo, Yong, Smith, Sidney C., Ge, Junbo, Ma, Changsheng, Han, Yaling, Fonarow, Gregg C. et al. · 2018 · Cardiovascular Diabetology
62. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
    The EMPA-KIDNEY Collaborative Group, Herrington, William G, Wanner, Christoph, Green, Jennifer B, Hauske, Sibylle J, Judge, Parminder, Mayne, Kaitlin J, Ng, Sarah Y A, Sammons, Emily, Zhu, Doreen et al. · 2022 · Nephrology Dialysis Transplantation
63. Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation
    Yumei Ye, Xiaoming Jia, Mandeep Bajaj, Yochai Birnbaum · 2018 · Cardiovascular Drugs and Therapy
64. Hyperglycemic Emergencies in Adults
    Jeannette Goguen, Jeremy D. Gilbert · 2018 · Canadian Journal of Diabetes
65. Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline
    Doyle-Delgado, Kacie, Chamberlain, James J., Shubrook, Jay H., Skolnik, Neil, Trujillo, Jennifer · 2020 · Annals of Internal Medicine
66. Disordered haematopoiesis and athero-thrombosis
    Andrew James Murphy, Alan R. Tall · 2016 · European Heart Journal
67. Efficacy of Empagliflozin on Heart Failure and Renal Outcomes in Patients with Atrial Fibrillation: Data from the EMPA-REG OUTCOME Trial
    Michael Böhm, Jonathan Slawik, Martina Brueckmann, Michaela Mattheus, Jyothis Thomas George, Anne Pernille Ofstad, Silvio E. Inzucchi, DAVID H. FITCHETT, Stefan D. Anker, Nikolaus Marx et al. · 2019 · European Journal of Heart Failure
68. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus
    Abhinav Sharma, Neha Jadeja Pagidipati, Robert M. Califf, Darren K. McGuire, Jennifer B. Green, Dave DeMets, Jyothis Thomas George, Hertzel C. Gerstein, Todd M. Hobbs, Rury R. Holman et al. · 2020 · Circulation
69. Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial
    Jesper Jensen, Massar Omar, Caroline Kistorp, Mikael Kjær Poulsen, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Jens Oscar Faber, Emil Loldrup Fosbøl et al. · 2020 · American Heart Journal
70. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes—Systematic review and meta-analysis of randomized placebo-controlled trials
    Husam M. Salah, Subhi Jamal Alaref, Muhammad Shahzeb Khan, Malek Al‐Hawwas, Srikanth Vallurupalli, Jawahar L. Mehta, John Paul Mounsey, Stephen John Greene, Darren K. McGuire, Renato D. Lópes et al. · 2020 · American Heart Journal
71. Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury
    Michał Wiciński, Eryk Wódkiewicz, Karol Maksymilian Górski, Maciej Walczak, Bartosz Malinowski · 2020 · Pharmaceuticals
72. SGLT2 Inhibitors as Calorie Restriction Mimetics: Insights on Longevity Pathways and Age-Related Diseases
    Caroline Wei Shan Hoong, Marvin Wei Jie Chua · 2021 · Endocrinology
73. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
    Giuseppe Palmiero, Arturo Cesaro, Erica Vetrano, Pia Clara Pafundi, Raffaele Galiero, Alfredo Caturano, Elisabetta Moscarella, Felice Gragnano, Teresa Salvatore, Luca Rinaldi et al. · 2021 · International Journal of Molecular Sciences
74. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin
    Rosalba La Grotta, Paola de Candia, Fabiola Olivieri, Giulia Matacchione, Angelica Giuliani, Maria Rita Rippo, Elena Tagliabue, Monica Mancino, Francesca Rispoli, Sabina Ferroni et al. · 2022 · Cellular and Molecular Life Sciences
75. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
    Dekkers, Claire C. J., Sjöström, C. David, Greasley, Peter J., Cain, Valerie, Boulton, David W., Heerspink, Hiddo J. L. · 2019 · Diabetes, Obesity and Metabolism
76. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice
    Baggio, Laurie L., Ussher, John R., McLean, Brent A., Cao, Xiemin, Kabir, M. Golam, Mulvihill, Erin E., Mighiu, Alexandra S., Zhang, Hangjun, Ludwig, Andreas, Seeley, Randy J. et al. · 2017 · Molecular Metabolism
77. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects
    André Jacques Scheen · 2016 · Expert Opinion on Drug Metabolism & Toxicology
78. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes
    Shin Kawasoe, Yukiko Maruguchi, Shoko Kajiya, Hitoshi Uenomachi, Masaaki Miyata, Mariko Kawasoe, Takuro Kubozono, Mitsuru Ohishi · 2017 · BMC Pharmacology and Toxicology
79. Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure
    Chang‐Myung Oh, Sungsoo Cho, Ji‐Yong Jang, Hyeongseok Kim, Sukyung Chun, Minkyung Choi, Sangkyu Park, Young‐Guk Ko · 2019 · Korean Circulation Journal
80. Nonalcoholic Steatohepatitis After Liver Transplantation
    Thomas Gerard Cotter, Michael Charlton · 2019 · Liver Transplantation
81. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis
    James Heyward, Omar Mansour, Lily Olson, Sonal Singh, G. Caleb Alexander · 2020 · PLoS ONE
82. Data extraction for epidemiological research (DExtER): a novel tool for automated clinical epidemiology studies
    Krishna Margadhamane Gokhale, Joht Singh Chandan, Konstantinos A. Toulis, Georgios V. Gkoutos, Peter Tiňo B, Krishnarajah Nirantharakumar · 2020 · European Journal of Epidemiology
83. Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
    Asmaa Elrakaybi, Katharina Laubner, Qian Zhou, Martin Johannes Hug, Jochen Seufert · 2022 · Molecular Metabolism
84. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial
    Lori M. Laffel, Thomas Danne, GEORGEANNA JONES KLINGENSMITH, William V. Tamborlane, Steven Matthew Willi, Philip Scott Zeitler, Dietmar Neubacher, Jan Marquard, Tatiana Prokop'evna Bardymova, Margarita Barrientos Pérez et al. · 2023 · The Lancet Diabetes & Endocrinology
85. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
    Lin, Donna Shu-Han, Lee, Jen-Kuang, Hung, Chi-Sheng, Chen, Wen-Jone · 2021 · Diabetologia
86. Effect of Aerobic and Resistance Exercise on Cardiac Adipose Tissues: Secondary Analyses From a Randomized Clinical Trial
    Christensen, Regitse Højgaard, Wedell-Neergaard, Anne-Sophie, Lehrskov, Louise Lang, Legaard, Grit Elster, Dorph, Emma, Larsen, Monica Korsager, Launbo, Natja, Fagerlind, Sabrina Ravn, Seide, Sidsel Kofoed, Nymand, Stine et al. · 2019 · JAMA Cardiology
87. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
    American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, Mandeep, McCoy, Rozalina G., Balapattabi, Kirthikaa, Bannuru, Raveendhara R., Bellini, Natalie J., Bennett, Allison K., Beverly, Elizabeth A., Briggs Early, Kathaleen, ChallaSivaKanaka, Sathyavathi et al. · 2026 · Diabetes Care
88. Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience
    Bernard Zinman, Steven P. Marso, Erik Christiansen, Salvatore Calanna, Søren Rasmussen, John B. Buse · 2018 · Diabetes Care
89. Dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats
    Krit Jaikumkao, Anchalee Pongchaidecha, Nuttawud Chueakula, Laongdao Thongnak, Keerati Wanchai, Varanuj Chatsudthipong, Nipon Chattipakorn, Anusorn Lungkaphin · 2018 · Diabetes Obesity and Metabolism
90. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
    Mei Qiu, Liang‐Liang Ding, Miao Zhang, Hairong Zhou · 2021 · Diabetes and Vascular Disease Research
91. Cardiac autonomic neuropathy and risk of cardiovascular disease and mortality in type 1 and type 2 diabetes: a meta-analysis
    Mahin Chowdhury, Sarah J Nevitt, Aikaterini Eleftheriadou, Prathap Kanagala, Hani Esa, Daniel James Cuthbertson, Abd A. Tahrani, Uazman Alam · 2021 · BMJ Open Diabetes Research & Care
92. SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy
    Xinyu Zhao, Shuangshuang Li, Ying-xin He et al. · 2023 · Annals of the Rheumatic Diseases
93. The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors
    Mohamed S. Dabour, Mina Y. George, MARY RAPHEL DANIEL, Anne Hudson Blaes, Beshay N. M. Zordoky · 2024 · JACC CardioOncology
94. An evidence-based screening tool for heart failure with preserved ejection fraction: the HFpEF-ABA score
    Yogesh N.V. Reddy, Rickey E. Carter, Varun Sundaram, David M. Kaye, M. Louis Handoko, Ryan James Tedford, Mads Jønsson Andersen, Kavita Sharma, Masaru Obokata, Frederik Hendrik Verbrugge et al. · 2024 · Nature Medicine
95. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
    American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, Mandeep, McCoy, Rozalina G., Balapattabi, Kirthikaa, Bannuru, Raveendhara R., Bellini, Natalie J., Bennett, Allison K., Beverly, Elizabeth A., Briggs Early, Kathaleen, ChallaSivaKanaka, Sathyavathi et al. · 2026 · Diabetes Care
96. SGLT2 Inhibitors: Benefit/Risk Balance
    André Jacques Scheen · 2016 · Current Diabetes Reports
97. Multimodality Strategy for Cardiovascular Risk Assessment
    James A. de Lemos, Colby R. Ayers, Benjamin D. Levine, Christopher R. deFilippi, Thomas J. Wang, William Gregory Hundley, Jarett D. Berry, Stephen L. Seliger, Darren K. McGuire, Pamela Ouyang et al. · 2017 · Circulation
98. New pharmacological strategies for protecting kidney function in type 2 diabetes
    Marcel H.A. Muskiet, David Collins. Wheeler, Hiddo J.L. Heerspink · 2018 · The Lancet Diabetes & Endocrinology
99. A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors
    Emily E. Brown, Surya Panicker Rajeev, Daniel James Cuthbertson, John P.H. Wilding · 2019 · Diabetes Obesity and Metabolism
100. Cardiac ketone body metabolism
     Azrul Abdul Kadir, Kieran Clarke, Rhys D Evans · 2020 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease